Cure8 research brief
Rising incidence in east and southeast Asia means more people will live with IBD over coming decades, which affects healthcare planning, access to specialists, and resource needs. Understanding regional trajectories can help prepare services and research priorities.
Clinicians, researchers, public-health planners in east and southeast Asia and other newly industrialised regions, and patient communities concerned about population-level increases in IBD.
The article maps IBD’s four-stage epidemiological model (emergence; acceleration in incidence; compounding prevalence; prevalence equilibrium) and applies it to Japan, South Korea, China, Hong Kong, and Malaysia, which are mostly in stage 2 (acceleration) at different phases.
The Review summarizes historical case reports and recent incidence/prevalence trends to show a region-wide shift that can inform planning for healthcare capacity, diagnosis, and long-term disease management.
The authors frame east and southeast Asia as a likely early example of a newly industrialised region moving toward stage 3; they suggest these patterns may forecast what other newly industrialised regions could experience as they undergo similar demographic and environmental changes.
This is a Review article summarized from the PubMed abstract and structured content; it synthesizes historical and recent epidemiological data rather than reporting a single new clinical trial or patient-level findings.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of interests GGK has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Celltrion, and Takeda; has received grants for research from Ferring and for educational activities from AbbVie, Celltrion, Janssen, Pfizer, and Takeda; and shares ownership of a patent (treatment of inflammatory disorders, autoimmune disease, and primary biliary cholangitis; UTI limited partnership, assignee; patent WO2019046959A1; PCT/CA2018/051098; Sept 7, 2018), for which no product is on the market; if the product were to reach the market, both investigator and institution would be paid. SO has received speaking fees for invited lectures from Mitsubishi Tanabe Pharma and Mochida Pharmaceutical, and consulting fees from EA Pharma. SC has been a consultant for Sanofi. TH has received grant support from EA Pharma, Mitsubishi Tanabe Pharma Corporation, AbbVie, JIMRO, Zeria Pharmaceutical, Meiji HD, Nippon Kayaku, Takeda Pharmaceutical, Pfizer, Mochida Pharmaceutical, Boston Scientific; received consulting fees from Mitsubishi Tanabe Pharma, EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Eli Lilly, Gilead Sciences, Bristol Myers Squibb, Abivax, Chugai Pharmaceutical, MSD, JIMRO, and Mochida Pharmaceutical; and lecture fees from Mitsubishi Tanabe Pharma Corporation, EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Eli Lilly, Gilead Sciences, Bristol Myers Squibb, Mochida Pharmaceutical, JIMRO, Nippon Kayaku, and Kyorin Pharmaceutical; KM received honorarium for speaking or consultancy from AbbVie, Takeda, Janssen, Pfizer, Gilead, Celltrion, Eli Lilly, Bristol Myers Squibb, Mitsubishi Tanabe, EA Pharma, Mochida, Kyorin, Zeria, Kissei, and Nippon Kayaku; and research grants from AbbVie, Mochida, and EA Pharma. SCN has served as an advisory board member for Pfizer, Ferring, Janssen, and AbbVie; received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, AbbVie, and Takeda; is Director of the Microbiota I-Center; is a founder member, non-executive board director and non-executive scientific advisor of GenieBiome and MicroSigX Biotech Diagnostic, which is non-remunerative; is a shareholder of GenieBiome Holdings and MicroSigX Diagnostic Holdings; and receives patent royalties through her affiliated institutions; no patent or product related to IBD is currently on the market—if any were to reach the market, recipients of royalties will include inventors and institutions. All other authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD face an elevated lifetime risk of colitis-associated cancer; improved detection and risk prediction could lead to earlier treatment and better outcomes. AI could make surveillance more accurate and...
Microbial changes after ileocecal resection appear linked to the degree of postoperative inflammation; understanding these changes could help predict or prevent Crohn’s recurrence after surgery.
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
